Triveni Bio is a biotechnology company at the forefront of novel antibody-based therapies for immunological and inflammatory disorders. Using a genetics-informed, precision medicine approach, the company seeks to establish proof-of-concept early in the drug development process by leveraging deep insights into genetic and mechanistic biology.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/02/24 | $115,000,000 | Series B |
Atlas Venture Cormorant Asset Management Deep Track Capital Fidelity Management & Research Company Goldman Sachs  Invus OrbiMed Advisors Viking Global Investors | undisclosed |
